SLN Borrow Costs Jump 75% in a Month as Takeover Clock Ticks

Silence Therapeutics shares are up 127% over the past week, trading at $19.67. The cost to borrow them has risen 75% over the past month, reaching 1.26% as of 22 October.

Borrow Costs Follow the Rally

The cost to borrow SLN climbed from 0.16% on 8 October to a peak of 1.53% on 21 October before settling at 1.26%. That move tracks almost exactly with the share price surge. Availability remains comfortable at 390%, meaning roughly four shares sit available to borrow for every one currently lent out. The borrow market is tighter than it was a month ago but not distressed.

Short interest held flat through the rally period, at roughly 2.54 million shares, little changed from September levels. The rise in borrow costs therefore reflects repricing of the existing short book rather than a fresh wave of short sellers.

HC Wainwright Cuts, Consensus Collapses

The most consequential development in the analyst record came on 21 October. Patrick Trucchio at HC Wainwright, who had reiterated a Buy rating with a $75 target as recently as June 2026, downgraded to Neutral and cut his price target 73% to $20. The stock was trading around $19.61 when the note landed.

The consensus now sits at Hold: one Buy, four Holds, and a mean target of $19.75. The stock is effectively at the analyst consensus. Morgan Stanley maintained its Overweight rating in August with a $32 target, but that is now the outlier on the register.

Put Demand Spiked, Then Eased

Options positioning told a sharply bearish story mid-week. The put-call ratio hit 0.22 on 21 October and 0.21 on 20 October, each reading more than 2.8 standard deviations above the 20-day mean of 0.09. By 23 October, the PCR had fallen back to 0.14, still above average but no longer extreme. The 52-week high on the PCR is 0.52, so the spike was notable but well below the most defensive positioning seen over the past year.

Takeover Backdrop and Register Moves

The rally and analyst reset both trace to Merck KGaA acquisition speculation. ORTEX puts a 65% probability on SLN being deleted from the MSCI World Small index as a consequence of that transaction closing, with an estimated effective date of 16 February 2027 (dates are estimated, not confirmed by the index provider).

The activist register shows Richard Griffiths, the largest disclosed holder at 7.97% as last reported, cut his stake from 21.7% to 7.97% in filings through August 2026. Tetragon Financial Group added to its position, filing a 5.3% stake as of 13 October. Stakes are disclosed around the 5% threshold; holders dropping below may not file again.

Earnings are scheduled for 10 November. The two most recent quarterly prints produced a one-day move of plus 23% and minus 5% respectively.

---

Key data: CTB 1.26% (up 75% in one month). Availability 390%. PCR 0.14, off mid-week peak of 0.22. Analyst mean target $19.75 vs current price $19.67. Short interest 2.54 million shares, flat over the period.